Table 4: Summary of HSV-1 Replication-Competent Vectors Targeting Strategies

HSV Strain	Genetic Modification	Targeting Molecule	Targeting Tissue/Organ	Ref.
Targeting of Entry
KgBpK-gC-	Deletion in pK region of gB + deletion of gC		General	[251]
KgBpK-gC-EPO	Deletion in pK region of gB + deletion of gC	Insertion of gC-EPO fusion protein	EPO-receptor positive cells	[252]
KgBpK-gC:preS1ap	Deletion in pK region of gB + deletion of gC	Insertion of gC:preS1ap fusion protein	Hepatocytes HBV receptor expressing cells	[253]
R5111	Deletion in pK region of gB + deletion of HS binding regions of gC and gD	Insertion of gC-IL-13 and gD-IL-13 fusion molecules	IL-13Rα2 receptor expressing cells	[255]
KgBpK-gC-gD-	Deletion in pK region of gB + deletion of gC + deletion of gD	Pseudotyping with VSV-G	VSV susceptible cells	[254]
R-LM113	Modification of gD coding sequence	Insertion of gD-anti-HER2 single-chain antibody fusion molecule	HER-2-expressing tumour cells	[257, 258]
HSV1716	Modification of gD coding sequence	Insertion of gD-scFv anti-CD55or anti CD38 or anti-EGFR fusion molecules	Tumour cells	[259]
Targeting of Replication/Expression
CEAICP4;	Deletion of either ICP4 promoter	Substitution with CEA promoter	Tumour cells	[139]
CEAγ34.5	Deletion of ICP34.5 promoter	Substitution with CEA promoter	Tumour cells	[139]
DF3γ34.5	Deletion of ICP34.5 promoter	Substitution with DF3/MUC1 promoter/enhancer sequences promoter	DF3/MUC1 expressing tumour cells	[139, 249]
KeM34.5	G207 backbone	Insertion of Musashi1 promoter driving ICP34.5	Malignant glioma	[265, 266]
rQNestin34.5	G207 backbone	Insertion of rQNestin promoter driving ICP34.5	Brain tumours	[234]